Can patch testing with methylchloroisothiazolinone/methylisothiazolinone be optimized using a new diagnostic mix? - A multicenter study from the Swedish Contact Dermatitis Research Group.
allergic contact dermatitis
contact sensitization
delayed hypersensitivity
methylchloroisothiazolinone/methylisothiazolinone (MCI/MI)
mix
patch testing
Journal
Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
13
01
2020
revised:
02
02
2020
accepted:
05
02
2020
pubmed:
1
3
2020
medline:
9
1
2021
entrez:
1
3
2020
Statut:
ppublish
Résumé
Methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) and methylisothiazolinone (MI) are tested to detect contact allergy to these isothiazolinones. To study if an aqueous patch test preparation with MCI and MI in a mix of 0.015% and 0.2%, respectively, detects more contact allergies than the commonly used preparations of MCI/MI in 0.02% aq. and MI in 0.2% aq. A total of 1555 patients with dermatitis in five Swedish dermatology departments were tested consecutively with MCI/MI 0.215% aq., MCI/MI 0.02% aq., and MI 0.2% aq. The share of contact allergy to MCI/MI 0.215% aq., MCI/MI 0.02% aq., and MI 0.2% aq. varied in the test centers between 7.9% and 25.9%, 3.2% and 10.3%, and 5.8% and 12.3%, respectively. MCI/MI 0.215% aq. detected significantly more patch-test positive individuals than both MCI/MI 0.02% aq. (P < .001) and MI 0.2% aq. (P < .001), as well as either one of MCI/MI and MI (P < .001). In the patients only reacting to MCI/MI 0.215% aq., 57.7% were recorded as having a dermatitis that was explained or aggravated by exposure to either MCI/MI or MI. The results speak in favor of replacing the preparations MCI/MI 0.02% aq. and MI 0.2% aq. with MCI/MI 0.215% aq. as the screening substance in the Swedish baseline series, which has been implemented in 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) and methylisothiazolinone (MI) are tested to detect contact allergy to these isothiazolinones.
OBJECTIVES
OBJECTIVE
To study if an aqueous patch test preparation with MCI and MI in a mix of 0.015% and 0.2%, respectively, detects more contact allergies than the commonly used preparations of MCI/MI in 0.02% aq. and MI in 0.2% aq.
METHODS
METHODS
A total of 1555 patients with dermatitis in five Swedish dermatology departments were tested consecutively with MCI/MI 0.215% aq., MCI/MI 0.02% aq., and MI 0.2% aq.
RESULTS
RESULTS
The share of contact allergy to MCI/MI 0.215% aq., MCI/MI 0.02% aq., and MI 0.2% aq. varied in the test centers between 7.9% and 25.9%, 3.2% and 10.3%, and 5.8% and 12.3%, respectively. MCI/MI 0.215% aq. detected significantly more patch-test positive individuals than both MCI/MI 0.02% aq. (P < .001) and MI 0.2% aq. (P < .001), as well as either one of MCI/MI and MI (P < .001). In the patients only reacting to MCI/MI 0.215% aq., 57.7% were recorded as having a dermatitis that was explained or aggravated by exposure to either MCI/MI or MI.
CONCLUSION
CONCLUSIONS
The results speak in favor of replacing the preparations MCI/MI 0.02% aq. and MI 0.2% aq. with MCI/MI 0.215% aq. as the screening substance in the Swedish baseline series, which has been implemented in 2020.
Substances chimiques
Thiazoles
0
2-methyl-4-isothiazolin-3-one
229D0E1QFA
5-chloro-2-methyl-4-isothiazolin-3-one
DEL7T5QRPN
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-289Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Bruze M, Gruvberger B, Björkner B. Kathon CG - an unusual contact sensitizer. In: Maibach HI, Menné T, eds. Exogenous Dermatoses. Boca Raton, Ann Arbor, Boston: CRC Press Inc; 1990:283-298.
Bruze M, Dahlquist I, Fregert S, Gruvberger B, Persson K. Contact allergy to the active ingredients of Kathon CG. Contact Dermatitis. 1987;16(4):183-188.
Bruze M, Fregert S, Gruvberger B, Persson K. Contact allergy to the active ingredients of Kathon CG in the guinea pig. Acta Derm Venereol. 1987;67(4):315-320.
Isaksson M, Gruvberger B, Bruze M. Occupational contact allergy and dermatitis from methylisothiazolinone after contact with wallcovering glue and after a chemical burn from a biocide. Dermatitis. 2004;15(4):201-205.
Lundov MD, Opstrup MS, Johansen JD. Methylisothiazolinone contact allergy - a growing epidemic. Contact Dermatitis. 2013;69(5):271-275.
Svedman C, Andersen KE, Brandão FM, et al. Follow-up of the monitored levels of preservative sensitivity in Europe: overview of the years 2001-2008. Contact Dermatitis. 2012;67(5):312-314.
García-Gavín J, Vansina S, Kerre S, Naert A, Goossens A. Methylisothiazolinone, an emerging allergen in cosmetics? Contact Dermatitis. 2010;63(2):96-101.
Engfeldt M, Bråred-Christensson J, Isaksson M, et al. Swedish experiences from patch testing methylisothiazolinone separately. Acta Derm Venereol. 2015;95(6):717-719.
Ackermann L, Aalto-Korte K, Alanko K, et al. Contact sensitization to methylisothiazolinone in Finland-a multicentre study. Contact Dermatitis. 2011;64(1):49-53.
Isaksson M, Gruvberger B, Gonçalo M, Goossens A, Le Coz CJ, Bruze M. Repeated open application test with methylisothiazolinone in individuals sensitive to methylchloroisothiazolinone/methylisothiazolinone. Contact Dermatitis. 2014;70(4):244-246.
Lundov MD, Zachariae C, Johansen JD. Methylisothiazolinone contact allergy and dose-response relationships. Contact Dermatitis. 2011;64(6):330-336.
Bruze M, Engfeldt M, Gonçalo M, Goossens A. Recommendation to include methylisothiazolinone in the European baseline patch test series - on behalf of the European Society of Contact Dermatitis and the European Environmental and Contact Dermatitis Research Group. Contact Dermatitis. 2013;69(5):263-270.
Horev L, Isaksson M, Engfeldt M, Persson L, Ingber A, Bruze M. Preservatives in cosmetics in the Israeli market conform well to the EU legislation. J Eur Acad Dermatol Venereol. 2015;29(4):761-766.
Isaksson M, Gruvberger B, Frick-Engfeldt M, Bruze M. Which test chambers should be used for acetone, ethanol, and water solutions when patch testing? Contact Dermatitis. 2007;57(2):134-136.
Fregert S. Manual of Contact Dermatitis. 2nd ed. Copenhagen: Munksgaard; 1981.
Micallef L, Rodgers P. eulerAPE: drawing area-proportional 3-Venn diagrams using ellipses. PLoS One. 2014;9(7):e101717. https://doi.org/10.1371/journal.pone.0101717
Bruze M, Isaksson M, Gruvberger B, et al. Patch testing with methylchloroisothiazolinone/methylisothiazolinone 200 ppm aq. detects significantly more contact allergy than 100 ppm. A multicentre study within the European Environmental and Contact Dermatitis Research Group. Contact Dermatitis. 2014;71(1):31-34.
Engfeldt M, Ale I, Andersen KE, et al. Multicenter patch testing with methylchloroisothiazolinone/methylisothiazolinone in 100 and 200 ppm within the International Contact Dermatitis Research Group. Dermatitis. 2017;28(3):215-218.
Johansen JD, Aalto-Korte K, Agner T, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis. 2015;73(4):195-221.
Ahlgren C, Isaksson M, Möller H, Axéll T, Liedholm R, Bruze M. The necessity of a test reading after 1 week to detect late positive patch test reactions in patients with oral lichen lesions. Clin Oral Investig. 2014;18(5):1525-1531.
Frick-Engfeldt M, Isaksson M, Zimerson E, Bruze M. How to optimize patch testing with diphenylmethane diisocyanate. Contact Dermatitis. 2007;57(3):138-151.
Isaksson M. Corticosteroid contact allergy-the importance of late readings and testing with corticosteroids used by the patients. Contact Dermatitis. 2007;56(1):56-57.
Bruze M. Thoughts on how to improve the quality of multicentre patch test studies. Contact Dermatitis. 2016;74(3):168-174.
Isaksson M, Ale I, Andersen KE, et al. Revised baseline series of the International Contact Research Group. Dermatitis. 2020;31(1):e5-e7. https://doi.org/10.1097/DER.0000000000000532